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EDITORIAL
An evaluation of the pathogenesis of the gouty kidney
Recent observations of urate excretion by the
kidney in genetic overproducers of urate have con-
tributed to our understanding of the mechanisms of
renal damage in gout. Some of these overproducers
showed normal serum urate concentrations when
their urine urate excretions were high, putting them
at risk from uric acid crystalluria and calculi. Others
developed acute renal failure which was completely
reversed by an intense alkaline diuresis. Some
overproducers developed varying degrees of renal in-
sufficiency while others members of the same family
with the same genetic mutation retained normal renal
function. How can these observations be reconciled
with existing knowledge of the gouty kidney?
Gout is now recognized as a syndrome and does
not have a uniform pathogenesis, so that different
types of renal pathology would be expected in
different types of gout. Nonetheless, the most consis-
tent feature of the kidney in subjects with gout has
been the presence of crystalline deposits [1]. Optical
and X-ray crystallography have identified these
deposits as being either acicular (needle-shaped)
crystals of monosodium urate monohydrate or
deposits of pure uric acid [2-4]. Half of the molecules,
which at pH 7.4 exist as urate anions, are present in
the form of uric acid at a pH value of 5.7. The deposi-
tion of sodium urate crystals at near-physiological
pH from fluids containing high concentrations of
urate ions constitutes the basis for the formation of
microtophi within any tissue [5]. Within the kidney,
however, the renal concentrating processes result in
progressive increases in urate concentration towards
the papilla [6], where the sodium concentration is
also highest so that, under appropriate conditions,
there is an increased tendency to form interstitial
deposits of monosodium urate monohydrate. Depo-
sition as uric acid, on the other hand, occurs at the
lower pH which pertains within the lumen of the
renal tubule or collecting duct. Here, the most impor-
tant factor determining deposition, besides the lower
solubility of uric acid at an acid pH, is the concentra-
tion of uric acid in tubular urine, itself dependent
upon the total uric acid excretion and urine volume,
Although the different pathogenetic mechanisms for
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the formation of sodium urate and uric acid crystals
have been clearly distinguished and are conceptually
and clinically useful (Table 1), it remains to be seen
whether intratubular uric acid deposits can, after
basement membrane rupture, form a nidus for
sodium urate deposition and microtophus formation.
Suffice it to say, however, that experimental studies
of crystal deposition in rats with urate overproduc-
tion support the clear distinction between the two
processes [7]. Other pathological findings in gouty
kidneys—calculus formation, infection and
obstruction—are regarded as being secondary in
some way to the crystal formation [1]. The
pathogenesis of the nephrosclerosis and frequent
vascular changes is uncertain but increased platelet
surface activation and aggregation have been
reported in a large proportion of patients with
primary gout [8]. Glomerulosclerosis and other ap-
parently distinctive pathology in gouty kidneys [91
have not been shown, on electron microscopy, to
differ from the changes of hypertensive nephro-
sclerosis [10].
A major problem in understanding renal disease
associated with gout has been the difficulty of
deciding in an individual patient whether the gout or
the renal disease was the primary abnormality.
Because patients with primary gout could be seen to
develop renal disease [11] and because acute gout was
uncommon in advanced chronic renal failure [12,
131—probably due to reduced phagocytic activity by
polymorphs [14)—it was generally assumed that all
renal disease associated with gouty arthritis was
secondary to the gout. However, with improved
patient longevity resulting from better methods of
conservative management of chronic renal failure,
cases of gouty arthritis developing in subjects with
pre-existing renal disease of mild to moderate degree
were seen [15-17]. This tendency to hyperuricemia
and gout has, of course, been accentuated by the use
of orally administered diuretics. Chronic lead
nephropathy has also been recognized as one par-
ticular type of primary renal disease in which gouty
arthritis frequently occurs [18] and a high incidence
of gout has also been reported in subjects with
polycystic disease of the kidney [19]. Thus, some of
the confusion in the past concerning the pathogenesis
I; —
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Table 1. Features of urate/uric acid crystal deposition in the kidney
Type Sodium urate Uric acid
Form Acicular Amorphous
Site Interstitial Intraluminal
Result Microtophus Tubular obstruction
Development Insidious Acute
Reversibility Limited Complete if
treated adequately
Dependent upon Urate concentration
in interstitium
Uric acid
concentration in urine
of the renal disease of gout can probably be at-
tributed to a failure to differentiate gout secondary to
primary renal disease from renal disease secondary to
primary gout.
The recognition that a deficiency of hypoxanthine-
guanine phosphoribosyl-transferase (HGPRT) was
uniformly associated with overproduction of urate
[20, 21] meant that it became possible to identify a
group in whom the urate abnormality was primary
and renal disease was secondary to the urate
overproduction. Such subjects have been either
hemizygous males from families with moderate or
severe urate overproduction, or heterozygous females
in whom the abnormality of urate metabolism was
qualitatively the same, although of less severity [22,
23]. Clinical study of these patients with urate
overproduction due to HGPRT deficiency enabled
certain conclusions to be reached which could be syn-
thesized into a vital reconstruction of the
pathogenesis of their renal damage. The following
were the observations:
1) Both interstitial urate crystals and intratubular
uric acid deposits may co-exist. Studies in families
with HGPRT deficiency have shown the presence of
severe gout and renal disease in some family members
[22]. Pathological examination of the kidneys in such
a member (Index Case, Pedigree I, 40) showed in-
terstitial formation of microtophi as a reaction to
crystals of monosodium urate monohydrate (Fig. 1)
as well as casts containing amorphous uric acid
within collecting ducts (Fig. 2), which appeared on
occasions to be causing tubular obstruction.
Presumably, the urate crystals were deposited
because of the severe hyperuricemia, and the in-
tratubular uric acid because of the high urinary uric
acid excretion.
2) The serum urate concentration may be normal in
urale overproduction as long as urate excretion
balances production. The passage of a uric acid
calculus may antedate the development of gouty
arthritis by years [24] and this is also common in
reported cases of HGPRT deficiency. In studying
these patients, however, some have been shown to
have a normal serum urate concentration at a time
when the urinary urate excretion is excessive (e.g.,
patients RL, VB and MB [23]), thus explaining the
old observation of renal colic preceding gouty
arthritis. In such cases, the efficient renal mechanism
for urate excretion is shown by the high urate
clearance (up to 20 ml/min in RL) and by the high
percent renal excretion of labelled urate (exceeding
90% in seven days, with a normal value of 72%).
While elimination keeps pace with production, the
serum urate concentration is normal and the patient
is chiefly at risk from the high renal excretion of uric
acid. Some of these patients remain asymptomatic for
years and develop gouty arthritis only at an advanced
age (e.g., patient LB [22, 23]).
Fig. 1. Formation of a microtophus
around birefringent crystals of mono-
sodium urate monohydrate deposited
in the interstitial tissues of the kidney
in a patient with urate overproduction
due to HGPR T deficiency (Index case.
pedigree 1, 40).
L.
.4
Fig. 2. A cast containing uric acid
(stained black) with a collecting duct
from the same patient with urate
overproduction as is illustrated in
Fig. 1.
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3) Episodes of acute but reversible deterioration of
renal function may occur in association with excessive
urinary excretion of urate. A sudden deterioration of
renal function observed in an HGPRT-deficient
overproducer was due to inadvertent fluid restriction;
it was reversed completely by an intensive alkaline
diuresis (Fig. 3). Other subjects with genetic
overproduction of urate have shown acute deteriora-
tion of renal function during the first few weeks of
life, but have later shown a reversion of renal func-
tion to normal (e.g., patient RJ [22]). Such observa-
tions seem most consistent with episodes in which
tubules were obstructed by casts consisting largely of
uric acid similar to those seen at autopsy (Fig. 2) and
which could still be cleared by a diuresis. The situa-
tion is comparable with the urate overproduction as-
sociated with lymphomas and myeloproliferative dis-
ease [25], in which acute reversible uric acid
nephropathy is increasingly recognized [26, 27].
Although the patients were also hyperuricemic, the
rapid and complete reversibility of renal failure is
more consistent with intratubular uric acid deposi-
tion due to the high urinary uric acid concentration
than with urate crystal and microtophus formation
related to the high urate concentration in the serum.
This type of so-called "hyperuricemic nephropathy"
is rather a hyperuricosuric nephropathy.
4) Renal insufficiency may develop in some but not in
other overproducers with apparently similar degrees of
urate overproduction. Affected members of the one
kindred are likely to possess the same HGPRT muta-
tion [28], so that differences in its expression are due
either to other inherited factors (which are difficult to
quantitate) or to variables in life style and environ-
ment. One such variable is the habitual urine volume,
and values between 800 and 5,000 mi/day have been
noted in HGPRT-deficient subjects. It is difficult to
determine the truly representative value for any in-
dividual, but those who experienced renal colic or
who developed minor renal insufficiency have been
those who tended to maintain lower urine volumes
than unaffected members of the same family.
Although additional contributory factors cannot be
excluded, it is thus tempting to ascribe importance to
urine volume in determining which overproducers
(all with a urinary uric acid excretion rate exceeding I
g/24 h) are at risk from intratubular deposition of
uric acid. Studies have not been sufficiently numerous
to assess the precise etiology of other secondary
features of urate nephropathy, although it would
seem that infection in the urinary tract may occur
mg/lOOm!
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Alkaline diuresis
Fig. 3. Rapid deterioration of renal function due to inadequate fluid
intake in a patient with urate overproduction due to HGPRT defi-
ciency, which was reversed by a massive alkaline diuresis (modified
from Q J Med 42:423, 1973).
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with
Good renal excretory capacity for urate
High urinary uric acid
4,
Renal crystalluriatCalculi
Intratubular crystal deposition
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working hypothesis concerning the pathogenesis of
the gouty kidney (Fig. 5). Many subjects with urate
overproduction have a good renal excretory capacity
for urate and, while urate excretion keeps pace with
production, the serum urate concentration is normal
and the patient asymptomatic. Such a subject will
have a high urinary uric acid excretion and, if at any
time the concentration of urate or sodium or the pH
within the urine were such that urate became insolu-
ble, uric acid crystalluria and possibly renal colic
would result. If this were to occur within the renal
tubules with unrelieved obstruction by uric acid casts,
loss of functioning nephrons would occur, leading
eventually to a reduction in renal excretory capacity
(Fig. 5). Such a reduction in nephron function would
be associated with a reduction in the 24-hr renal ex-
cretion of uric acid which would disturb the balance
between production of urate and its excretion, and
result in the development of hyperuricemia. A suffi-
cient degree of hyperuricemia sustained for a suffi-
Overproduction of urate
whenever there has been crystalluria, and that
hypertension is not an early development in urate
overproduction, but rather a sequel to either struc-
tural or functional evidence of renal disease [29].
5) The development of renal insufficiency is as-
sociated with a progressive reduction in the 24-hr
urinary excretion of uric acid. In health, urate
homeostasis is maintained by the excretion of the ma-
jor proportion of produced urate via the kidney, the
minor proportion being excreted into the alimentary
tract secretions, presumably by a passive process [30].
With the onset of renal insufficiency, the fall in urate
clearance is proportionately less than the fall in in-
ulin or creatinine clearance [31, 32]. This has been
shown to be the result of an actual increase in urate
excretion per nephron, due to varying combinations
of reduced reabsorption and increased tubular secre-
tion of urate [33, 34]. However, when looked at in ab-
solute terms, the total renal excretion of urate falls
progressively with the development and progression
of renal disease. This can be seen in relation to the 24-
hr urinary excretion of urate and the creatinine
clearance in our own series of patients with varying
degrees of renal insufficiency and various types of
renal disease (Fig. 4). It can also be confirmed by
calculation from the data of Steele and Rieselbach
[33] where there is a significant regression of the
urinary excretion (UV) of urate on inulin clearance,
the UV of urate falling from about 600 jig/mm at in-
ulin clearance of 100 mI/mm to about 300 jig/mm at
an inulin clearance of 10 mI/mm.
These observations of urate kinetics in genetic
overproducers of urate and in renal failure can be
synthesized with previous knowledge concerning the
nature of urate deposits with the kidney to give a
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Fig. 5. Scheme to illustrate the various pathogenetic mechanisms by
which urate overproduction may lead to renal insufficiency.
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Creatinine clearance, mt/mm
Fig. 4. The fall in the renal excretion of urate which occurs with
reduction in renal glomerular excretory function.
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cient period would result in gouty arthritis. However,
the reduced glomerular function (which might still be
within the normal range) would lead to a reduction in
the total 24-hr renal excretion of uric acid, which,
although less than at the time when renal function
was completely normal, would still be sufficiently
large either in amount or concentration for nephron
obstruction and loss of function to continue to occur.
This, if not reversed, could lead ultimately to a more
severe degree of hyperuricemia and further reduction
in the 24-hr urinary excretion of urate. This reduction
in renal excretion of urate would eventually reduce to
negligible proportions the tendency to intratubular
uric acid deposition, crystalluria and calculus forma-
tion. By this stage, however, hyperuricemia would
have become severe, leading, on the one hand, to the
development of severe gouty arthritis with tophus
formation and, on the other hand, to the develop-
ment of urate-induced renal damage by the second
mechanism, namely the formation of monosodium
urate monohydrate crystals within the renal
parenchyma. Further renal insufficiency could arise
from interference with nephron function by the as-
sociated microtophi.
The primary nephropathy may thus be considered
to result directly from the deposition of urate either
as monosodium urate crystals within the interstitium
or in the form of uric acid within tubules. The secon-
dary nephropathy would result from superimposed
infection or hypertension or both, the former
predisposed to by obstruction or interstitial fibrosis.
The precise mechanism by which hypertension may
supervene at this stage is as yet ill-understood, but
could be contributed to by both renal factors (such as
involvement of the juxtaglomerular apparatus by
microtophus formation) as well as systemic ones such
as obesity, hypertriglyceridemia and degenerative
vascular disease. Thus, a secondary nephropathy
related to infection, hypertension and vascular dis-
ease may be superimposed on the primary
nephropathy due to crystal deposition, together
resulting in the development of renal insufficiency.
Progression of the primary urate nephropathy may
be prevented at any stage by therapy which reduces
the concentration of urate below that necessary for
crystal formation within either interstitial tissue or
tubular urine.
The applicability of such an hypothesis based on
observation in subjects with urate overproduction to
the subject with gout who does not have evidence of
overproduction of uric acid may be argued. However,
provided it is accepted that the tendency to urate
crystal deposition is less in a normal producer than in
an overproducer, the same sequence of events is pos-
sible in a person with normal production, particularly
when it is remembered that the urine concentration of
uric acid in such a person may reach a similar con-
centration to that in an overproducer if the normal
producer has a high purine intake or a poor urine
volume or both at any time. On the other hand, it
should be emphasized that the above sequence will be
unlikely to occur in gouty subjects whose
hyperuricemia is due to renal underexcretion of
urate, who would be at less risk of intratubular uric
acid deposition, but at an equal risk of micotophus
formation when hyperuricemia of sufficient degree is
present. Evidence to date is insufficient to determine
whether subjects whose hyperuricemia is due to
primary underexcretion of urate—e.g., those with
genetic underexcretion or whose underexcretion is
due to hypertension, diuretics, lactatemia or
ketonemia—do demonstrate an incidence of renal
disease comparable with that of overproducers of
urate; indeed, personal observations suggest that
renal complications are less common features of the
type of gout under question, unless the associated
hyperuricemia is severe.
Thus, documentation of the prevalence of renal
disease in patients with different types of gout and
differing degrees of hyperuricemia should throw light
on the general applicability of this hypothesis to the
pathogenesis of the gouty kidney.
Now that drugs can reduce the hyperuricemia of
renal failure, the important question of the contribu-
tion of uric acid to aggravation of renal disease needs
consideration. First, most patients with primary renal
disease are underexcretors of urate, and therefore, ex-
cept during periods of oliguria, are rarely at risk from
intratubular deposition of uric acid. Most are
hyperuricemic from an early stage in their renal dis-
ease, however, although the degree of hyperuricemia
in the uncomplicated situation is usually only
moderate in degree (less than 10 ml/100 ml) and does
not rise with progressive renal insufficiency until
severe renal failure (glomerular filtration rate, GFR,
less than 15 mI/mm) is reached [18, 33, 34]. Severe
hyperuricemia (greater than 10 ml/lOO ml) in associa-
tion with renal disease should prompt the search for a
cause, such as an acute reversible renal insufficiency,
urate overproduction (as in myeloproliferative dis-
orders), plasma volume contraction [35] and un-
controlled hypertension or diuretic therapy. Very few
studies of the possible benefit of reducing the
hyperuricemia of chronic renal disease by allopurinol
have been carred out. However, Rosenfeld [36], in a
well controlled study, has shown that normalization
of serum urate concentrations does not significantly
alter the rate of change of renal function in patients
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with asymptomatic hyperuricemia, hypertension or
renal disease with a GFR as low as 40 mI/mm. Most
of his patients had only moderate hyperuricemia,
however (less than 10 ml/100 ml), so that, while his
results suggest that allopurinol is not indicated in
most patients with chronic renal failure, the position
needs further examination in those patients with per-
sistent severe hyperuricemia and another carefully
controlled clinical trial in such a group is needed. Un-
til this is done, the physician, knowing that the risk of
monosodium urate crystal deposition in primary gout
increases steadily with increasing serum urate con-
centrations, will need to balance the risk of renal
microtophus formation [37, 38] against the increased
risk of drug reactions in renal failure. It is worth
noting, however, that the hyperuricemia due to
chronic renal diseases is often particularly susceptible
to restriction of dietary purines [39] and that it would
be prudent to correct contributory factors, such as
plasma volume contraction, severe hypertension or
diuretic administration before embarking upon drug
therapy.
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